文献速递胃肠外科

病理完全缓解能否作为可切除食管癌总生存期的替代终点:III期试验个体患者数据整合分析

Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials.
PubMed 文献 · Br J Surg · 2025-01-01

该研究整合10项III期试验共1641例可切除食管或胃食管交界癌患者的个体数据,评估病理完全缓解(pCR)与总生存期(OS)的个体水平替代关系。新辅助化疗(NAC)亚组pCR率7.2%,新辅助放化疗(NACRT)亚组29.4%;两亚组Kendall秩相关系数τ分别为0.256和0.174,均远低于预设的良好替代阈值0.8。结论认为pCR虽与OS相关,但未证实个体水平替代性,不宜作为可切除食管癌OS的替代终点。

要点

  • pCR与OS相关,但个体水平τ仅0.256(NAC)和0.174(NACRT),远低于0.8阈值。
  • NAC亚组pCR者OS的HR为0.12,NACRT亚组为0.57,C-index均约0.54-0.56。
  • 模拟数据提示达到强替代(τ=0.8)需HR低至0.09,现实中难以实现。

核心结论

  • pCR与OS存在相关性,但未证实个体水平替代性,pCR不宜作为可切除食管癌OS的替代终点。

研究设计与样本

  • 整合分析III期试验个体患者数据,比较可切除食管及胃食管交界癌围手术期治疗。
  • 22项合格试验中10项提供个体数据,共1641例患者。
  • NAC亚组624例,其中45例(7.2%)达到pCR;NACRT亚组1017例,其中299例(29.4%)达到pCR。
  • 采用Kendall秩相关系数τ评估个体水平替代性,τ=0.8为良好替代阈值。
  • 提出一种基于逆概率删失加权估计量并校正结值的新方法估计有序终点与OS间的τ。

主要发现

  • NAC亚组pCR者OS的HR为0.12(95%CI 0.05-0.33),C-index为0.54(95%CI 0.52-0.56),τ为0.256。
  • NACRT亚组pCR者OS的HR为0.57(95%CI 0.47-0.70),C-index为0.56(95%CI 0.54-0.58),τ为0.174。
  • 模拟数据提示达到强替代(τ=0.8)需HR为0.09(95%CI 0.07-0.11)。

关键数值与推荐

  • 个体水平替代性良好阈值预设为τ=0.8。
  • NAC亚组τ=0.256,NACRT亚组τ=0.174,均未达到0.8。
  • NAC亚组pCR率7.2%(45/624),NACRT亚组pCR率29.4%(299/1017)。

临床怎么用

  • 在可切除食管癌围手术期治疗试验中,不应以pCR替代OS作为主要疗效终点。
  • pCR可作为支持性指标,但OS仍是评价治疗获益的标准终点。
  • 解读pCR获益时需结合治疗类型(NAC vs NACRT),两者替代性均不足。

局限性

  • 仅10/22项合格试验提供个体数据,可能存在选择偏倚。
  • NAC亚组pCR事件数较少(45例),估计稳定性受限。
  • 研究提出新方法估计τ,其方法学性能需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overall survival (OS) is the standard endpoint for oncological treatment efficacy, but requires long follow-up. The aim of this study was to evaluate pCR as a surrogate for OS in oesophageal cancer. METHODS: An integrated analysis of individual patient data (IPD) from phase III trials comparing perioperative therapies for resectable oesophageal and gastro-oesophageal junction cancer was conducted. Individual-level surrogacy between pCR and OS was assessed using Kendall's rank correlation coefficient (τ). A τ of 0.8 was considered a threshold for a good surrogate. As no method estimating τ between an ordinal endpoint and OS has been reported, a new method was proposed using the inverse-probability-of-censoring weighted estimator adjusted for tied data. RESULTS: Of 22 eligible trials, 10 provided IPD for 1641 patients, including 624 who received neoadjuvant chemotherapy (NAC; 45 (7.2%) achieved pCR) and 1017 who received neoadjuvant chemoradiotherapy (NACRT; 299 (29.4%) achieved pCR). In the NAC subgroup, patients with pCR had an HR for OS of 0.12 (95% c.i. 0.05 to 0.33), the C-index was 0.54 (95% c.i. 0.52 to 0.56), and τ was 0.256. In the NACRT subgroup, the HR was 0.57 (95% c.i. 0.47 to 0.70), the C-index was 0.56 (95% c.i. 0.54 to 0.58), and τ was 0.174. Hypothetical data suggested that achieving strong surrogacy (τ of 0.8) required an HR of 0.09 (95% c.i. 0.07 to 0.11). CONCLUSION: Although pCR was correlated with OS, no evidence of individual-level surrogacy with OS was demonstrated, making it inappropriate to consider pCR as a surrogate endpoint for OS in resectable oesophageal cancer.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Okui J, Nagashima K, Matsuda S, et al. Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials. Br J Surg. 2025. PMID: 40568913. doi:10.1093/bjs/znaf131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。